Nuwellis Unveils 24-Hour Aquadex Circuit for Fluid Management
Nuwellis, Inc., a prominent player in fluid management, has recently announced its intent to introduce a new 24-hour Aquadex circuit that will make its debut in the fall. This development marks an essential advancement in outpatient therapy options for patients needing fluid management without the necessity of hospitalization.
Enhancing Outpatient Care with a New Therapy Option
The introduction of the 24-hour circuit aims to cater to a growing need for structured outpatient care within hospitals. This innovative option aligns seamlessly with existing 72-hour treatments, empowering healthcare providers to deliver tailored therapy based on their patients' needs.
As more hospitals develop outpatient Aquadex programs, the need for reliable treatment pathways becomes increasingly apparent. The new circuit matches the workflows typical of a single-visit model, streamlining scheduling, implementation, and operational efficiency. Patients will benefit from a coherent same-day therapy experience, while providers can efficiently execute clinic operations.
Commentary from Nuwellis Leadership
“The demand for outpatient Aquadex therapy is gaining traction, offering patients an effective route for fluid management without needing admission,” shared John Erb, Chairman and CEO of Nuwellis. “With the addition of the 24-hour circuit, we are focusing on expanding access to Aquadex therapy, ensuring consistent and high-quality care across outpatient settings.”
Resources and Support for Outpatient Programs
Nuwellis is committed to providing comprehensive resources for hospitals looking to pioneer or enhance their outpatient Aquadex programs. The company offers guidance on patient identification and staff training, ensuring healthcare teams are well-equipped to implement these innovative therapies in outpatient environments. This support underscores Nuwellis' dedication to improving patient outcomes through effective fluid management practices.
About Nuwellis and the Aquadex SmartFlow System
Nuwellis, Inc. (NASDAQ: NUWE) is a medical device firm driven by the mission to better the lives of patients struggling with fluid overload. The company is focused on the commercialization of the Aquadex SmartFlow system for ultrafiltration therapy. The system is revolutionary in its clinically proven method to remove excess fluid from adults and children suffering from hypervolemia.
The Aquadex SmartFlow system is indicated for both temporary and extended use in patients not adequately responding to traditional medical management. Every treatment is administered by trained healthcare professionals in clinical settings, ensuring optimal safety and efficacy for all patients involved.
Frequently Asked Questions
What is the primary function of Nuwellis' new 24-hour Aquadex circuit?
The new circuit is designed to facilitate single-day outpatient therapy for fluid management, allowing for predictable patient care without hospital admission.
How does the 24-hour circuit improve outpatient care?
By aligning with single-visit workflows, the circuit simplifies scheduling and enhances operational efficiency, making outpatient treatment more manageable for healthcare providers.
What does Nuwellis provide to support outpatient programs?
Nuwellis offers resources such as patient identification protocols, implementation strategies, and staff education to assist hospitals in establishing or enhancing their Aquadex therapy programs.
How does the Aquadex SmartFlow system work?
The system uses clinically validated techniques to remove excess fluid from patients with hypervolemia, administered under the supervision of trained professionals.
What are the future prospects for Nuwellis?
Nuwellis continues to innovate in the medical device space, ensuring improved access to their therapies and aiming for expanded market presence in outpatient care.
